
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Orlando, Fla. - Patients with psoriasis are at higher risk for celiac disease than the general population, according to Veronica Ojetti, M.D., a gastroenterologist at Gemelli Hospital in Rome.